

Press Release.

Opella and Verb Biotics join forces for gut health.

France, 12 March 2026 – Opella announces a strategic and exclusive partnership with Verb Biotics for the development of a next-generation probiotic strain and its commercialization. This collaboration merges Opella’s ability to take ideas from concept to execution at global scale with Verb Biotics’ cutting-edge microbiome research to discover probiotic strains and deliver targeted health benefits in digestive wellness, among other areas.

The microbiome is a key innovation priority for Opella, and seeking startups and scale-ups with unique capabilities that complement its R&D priorities is part of its innovation strategy. This partnership aims to support the growth of Opella’s brands, with solutions in digestive wellness and interconnected health benefits based on Verb Biotics advanced microbiome technology.

A B2B biotechnology company, Verb Biotics specializes in discovering and delivering clinically validated microbiome ingredients for the food, beverage, and supplement industries. Their strategy to identify new bacteria strains based on their biological activities to support specific health benefits mirrors Opella’s mission to bring health in people’s hands through science-backed solutions.

Dr. Josephine Fubara. Chief Science Officer, Opella.

“We’re flipping the script on what it means to power well-being from within. Partnering with Verb Biotics helps us push the boundaries of microbiome science and strip away the guesswork for consumers. Together, we will set a new standard: clinically proven gut health solutions, ready for real life.”

Todd Beckman. Chief Executive Officer, Verb Biotics.

“Our partnership with Opella is a catalyst for innovation. By bringing together pioneering research and a bold commitment to consumer health, we’re setting the stage for transformative solutions that empower people to thrive.”

By combining forces, the companies aim to translate rigorous science into accessible, effective health solutions that people can trust. The goal is simple: hard science made easy for better health.

About Opella.

Opella is the self-care challenger with the purest and third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people’s hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting. At the core of this mission is our 100 loved brands, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many of the world’s most loved brands, including Allegra, Buscopan, Doliprane, Dulcolax, Enterogermina, Essentiale and Mucosolvan. B Corp certified globally, we are active players in the journey towards healthier people and planet.

Find out more about our mission at www.opella.com.

Press Contacts.

Justine Rohée. justine.rohee@sanofi.com. +33 6 86 47 85 60.

Natacha Kalasa. natacha.kalasa@sanofi.com. +33 6 72 16 64 61.

Celestia Howe, Verb Biotics, celestiah@verbbiotics.com. +1 303-807-6594.